China Anti-Flu Baloxavir Marboxil New Spot Raw Materials CAS 1985606-14-1, Find details about China Baloxavir Marboxil, Apis Baloxavir Marboxil from Anti-Flu Baloxavir Marboxil New Spot Raw Materials CAS 1985606-14-1
Product Name: Baloxavir marboxil
Synonyms: CS-2794;S-033188;S-033188;XOFLUZA;Xofluza;aloxavir marboxil;Baloxavir marboxil;baloxavir marboxil S-033188
CAS: 1985606-14-1
MF: C27H23F2N3O7S
Boiling point: 712.8±70.0 °C
Density: 1.57±0.1 g/cm3
Description:
Baloxavir marboxil is an antiviral drug developed by Shionogi Co., a Japanese pharmaceutical company and Roche for the treatment of influenza A and influenza B infections. The drug was initially approved for use in Japan in February 2018 and approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours Label. Baloxavir marboxil, a cap-endonuclease inhibitor, has a unique mechanism of action when compared to the currently existing neuraminidase inhibitor drug class used to treat influenza infections.